Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.

Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS.

Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23.

PMID:
31015198
2.

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C.

Gynecol Oncol. 2018 Dec;151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001. Epub 2018 Oct 8.

PMID:
30309721
3.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
4.

Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.

Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS.

Menopause. 2016 Nov;23(11):1228-1232.

5.

Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study.

Brooks SE, Carter RL, Plaxe SC, Basen-Engquist KM, Rodriguez M, Kauderer J, Walker JL, Myers TK, Drake JG, Havrilesky LJ, Van Le L, Landrum LM, Brown CL.

Gynecol Oncol. 2015 Jul;138(1):101-8. doi: 10.1016/j.ygyno.2015.04.033. Epub 2015 Apr 30.

6.

Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.

Chase DM, Kauderer J, Wenzel L, Ramondetta L, Cella D, Long HJ 3rd, Monk BJ.

Int J Gynecol Cancer. 2015 Feb;25(2):303-8. doi: 10.1097/IGC.0000000000000328.

8.

Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study.

Liao SY, Rodgers WH, Kauderer J, Darcy KM, Carter R, Susumu N, Nagao S, Walker JL, Hatae M, Stanbridge EJ.

Br J Cancer. 2013 Feb 19;108(3):613-20. doi: 10.1038/bjc.2012.578. Epub 2013 Jan 8.

9.

A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Carter RL, Kang L, Darcy KM, Kauderer J, Liao SY, Rodgers WH, Walker JL, Lankes HA, Dunn ST, Stanbridge EJ.

Cancer Causes Control. 2012 Dec;23(12):2013-21. doi: 10.1007/s10552-012-0081-0. Epub 2012 Oct 17.

10.

Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Bartels PH, Garcia FA, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Alberts DS.

Gynecol Oncol. 2012 Apr;125(1):129-35. doi: 10.1016/j.ygyno.2011.12.422. Epub 2011 Dec 9.

11.

Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study.

Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Darcy KM, Carter R, Levine L, Spirtos NM, Susumu N, Fujiwara K, Walker JL, Hatae M, Stanbridge EJ.

Br J Cancer. 2011 Jan 18;104(2):353-60. doi: 10.1038/sj.bjc.6606049. Epub 2010 Dec 14.

12.

Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.

Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ.

Int J Cancer. 2009 Nov 15;125(10):2434-40. doi: 10.1002/ijc.24615.

13.

A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study.

Carlson JW, Kauderer J, Walker JL, Gold MA, O'Malley D, Tuller E, Clarke-Pearson DL; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Jul;110(1):76-82. doi: 10.1016/j.ygyno.2008.03.005. Epub 2008 May 15.

PMID:
18482765
14.

Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study.

Mutter GL, Kauderer J, Baak JP, Alberts D; Gynecologic Oncology Group.

Hum Pathol. 2008 Jun;39(6):866-74. doi: 10.1016/j.humpath.2007.09.023. Epub 2008 Apr 23.

15.

Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, Gallup DG.

Cancer. 2006 Feb 15;106(4):804-11.

16.

Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J.

Cancer. 2006 Feb 15;106(4):812-9.

17.

Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.

Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H; Gynecologic Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):630-4.

PMID:
15721404
18.

Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.

Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK.

Gynecol Oncol. 2004 Dec;95(3):496-9.

PMID:
15581952
19.

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.

Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L.

Gynecol Oncol. 2004 Aug;94(2):368-74. Erratum in: Gynecol Oncol. 2004 Dec;95(3):778.

PMID:
15297174

Supplemental Content

Loading ...
Support Center